menu
    • menu

    Company profile for Topas Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Topas Therapeutics is focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas Particle Conjugates mimic s...
    Topas Therapeutics is focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. Topas’ technology platform induces antigen-specific immune tolerance by utilizing the liver’s natural immunology capabilities, targeting liver sinusoidal endothelial cells (LSECs), which generate tolerance against bloodborne antigens. Topas Particle Conjugates mimic such bloodborne antigens and follow their natural processing in LSECs, including the generation of long-lasting antigen-specific regulatory T cells (Tregs).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Topas TherapeuticsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Falkenried 88, Haus A 20251 Hamburg
    Telephone
    Telephone
    +49 40 302089010
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://topas-therapeutics.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TPM502 Shows Positive Ph 2a Data In Celiac Disease
    TPM502 Shows Positive Ph 2a Data In Celiac Disease

    06 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/06/3074893/0/en/Topas-Therapeutics-TPM502-Achieves-Gluten-specific-Tolerance-Induction-Positive-Safety-Profile-in-Phase-2a-Trial-in-Celiac-Disease-Patients.html

    GLOBENEWSWIRE
    06 May 2025
    Share Share
    Topas Presents Phase 2a Data for TPM502 at Digestive Week
    Topas Presents Phase 2a Data for TPM502 at Digestive Week

    24 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250424473586/en/Topas-Therapeutics-Announces-Presentation-of-Phase-2a-Data-for-TPM502-in-Celiac-Disease-at-Digestive-Disease-Week-2025-in-San-Diego

    BUSINESSWIRE
    24 Apr 2025
    Share Share
    Topas Therapeutics Shows Tolerance Induction with Nanoparticles
    Topas Therapeutics Shows Tolerance Induction with Nanoparticles

    17 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250317035258/en/Topas-Therapeutics-Publishes-Foundational-Data-Demonstrating-Tolerance-Induction-by-its-Proprietary-Nanoparticle-Platform-in-Frontiers-in-Immunology

    BUSINESSWIRE
    17 Mar 2025
    Share Share
    Topas Announces Positive Results For TPM502 In Celiac Disease
    Topas Announces Positive Results For TPM502 In Celiac Disease

    15 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241015961357/en

    BUSINESSWIRE
    15 Oct 2024
    Share Share
    Topas Therapeutics Appoints Hugo Fry as CEO
    Topas Therapeutics Appoints Hugo Fry as CEO

    07 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240507504752/en

    BUSINESSWIRE
    07 May 2024
    Share Share
    Topas launches Phase IIa trial of celiac disease therapy
    Topas launches Phase IIa trial of celiac disease therapy

    26 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/topas-phase-iia-celiac-disease-therapy/

    CLINICAL TRIALS ARENA
    26 May 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search